Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

Multicenter, randomized, open-label, parallel-group study to evaluate user satisfaction with and tolerability of the low-dose levonorgestrel (LNG) intrauterine delivery system (IUS) with 12 µg LNG/day initial in vitro release rate (LCS12) in comparison to a combined oral contraceptive containing 30 µg ethinyl estradiol and 3 mg drospirenone (Yasmin®) in young women (18-29 years) over 18 months of use
Levonorgestrel
13362
NCT01254292
Contraception
Phase 3
 
December 2016

Powered by ideaPoint, Inc.